1987-2000

This page in English

2000

Dehydroepiandrosterone in the treatment of systemic lupus erythematosus.
van Vollenhoven R
Rheumatology (Oxford) 2000 Aug;39(8):929-30

Dehydroepiandrosterone in systemic lupus erythematosus.
van Vollenhoven R
Rheum. Dis. Clin. North Am. 2000 May;26(2):349-62

1999

Psychosocial correlates of morbidity in women with systemic lupus erythematosus.
Ward M, Lotstein D, Bush T, Lambert R, van Vollenhoven R, Neuwelt C
J. Rheumatol. 1999 Oct;26(10):2153-8

VH4-34 encoded antibodies in systemic lupus erythematosus: a specific diagnostic marker that correlates with clinical disease characteristics.
van Vollenhoven R, Bieber M, Powell M, Gupta P, Bhat N, Richards K, et al
J. Rheumatol. 1999 Aug;26(8):1727-33

Treatment of severe CNS lupus with intravenous immunoglobulin.
Engel G, van Vollenhoven R
J Clin Rheumatol 1999 Aug;5(4):228-32

A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus.
van Vollenhoven R, Park J, Genovese M, West J, McGuire J
Lupus 1999 ;8(3):181-7

Influence of hormonal events on disease expression in patients with the combination of systemic lupus erythematosus and rheumatoid arthritis.
Sundaramurthy S, Karsevar M, van Vollenhoven R
J Clin Rheumatol 1999 Feb;5(1):9-16

Severe rheumatoid arthritis.
van Vollenhoven R
J. Rheumatol. 1999 Jan;26(1):197

1998

Dehydroepiandrosterone in systemic lupus erythematosus: relationship between dosage, serum levels, and clinical response.
Barry N, McGuire J, van Vollenhoven R
J. Rheumatol. 1998 Dec;25(12):2352-6

"Rheumatology in primary care - A five-article symposium"
van Vollenhoven R
Postgraduate Medicine. 1998; 103(2):67

Role of sex steroids in the Th1/Th2 cytokine balance: comment on the article by Miossec and van den Berg.
van Vollenhoven R
Arthritis Rheum. 1998 Oct;41(10):1897-8

Socioeconomic status and health in women with systemic lupus erythematosus.
Lotstein D, Ward M, Bush T, Lambert R, van Vollenhoven R, Neuwelt C
J. Rheumatol. 1998 Sep;25(9):1720-9

Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.
van Vollenhoven R, Morabito L, Engleman E, McGuire J
J. Rheumatol. 1998 Feb;25(2):285-9

Corticosteroids in rheumatic disease. Understanding their effects is key to their use.
van Vollenhoven R
Postgrad Med 1998 Feb;103(2):137-42

Rheumatoid arthritis. Designing and implementing a treatment plan.
Gremillion R, van Vollenhoven R
Postgrad Med 1998 Feb;103(2):103-6, 110, 116-8 passim

1997

Skeletal status of men with early and late ankylosing spondylitis.
Lee Y, Schlotzhauer T, Ott S, van Vollenhoven R, Hunter J, Shapiro J, et al
Am. J. Med. 1997 Sep;103(3):233-41

1996

Studies of dehydroepiandrosterone (DHEA) as a therapeutic agent in systemic lupus erythematosus.
Van Vollenhoven R, McGuire J
Ann Med Interne (Paris) 1996 ;147(4):290-6

"Hormones and systemic lupus erythematousus"
van Vollenhoven R
Annales de medecine interne. 1996;147(4):239-240

Systemic lupus erythematosus and pregnancy.
Druzin M, Van Vollenhoven R
Ann Med Interne (Paris) 1996 ;147(4):265-73

1995

Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial.
van Vollenhoven R, Engleman E, McGuire J
Arthritis Rheum. 1995 Dec;38(12):1826-31

Breast implants and connective-tissue diseases.
van Vollenhoven R
N. Engl. J. Med. 1995 Nov;333(21):1424

Adhesion molecules, sex steroids, and the pathogenesis of vasculitis syndromes.
van Vollenhoven R
Curr Opin Rheumatol 1995 Jan;7(1):4-10

1994

An open study of dehydroepiandrosterone in systemic lupus erythematosus.
van Vollenhoven R, Engleman E, McGuire J
Arthritis Rheum. 1994 Sep;37(9):1305-10

Estrogen, progesterone, and testosterone: can they be used to treat autoimmune diseases?
Van Vollenhoven R, McGuire J
Cleve Clin J Med ;61(4):276-84

1990

Exposure of female mice to type II collagen reduces susceptibility to collagen-induced arthritis in offspring.
Van Vollenhoven R, Thorbecke G, Siskind G
Eur. J. Immunol. 1990 Sep;20(9):2149-52

1989

Serum IgD levels in mice: effect of strain, age and autoimmune disease.
van Vollenhoven R, Swenson C, Soriano A, Goidl E, Coico R, Thorbecke G, et al
J. Autoimmun. 1989 Jun;2(3):259-67

1988

The role of immunity to cartilage proteoglycan in adjuvant arthritis. Intravenous injection of bovine proteoglycan enhances adjuvant arthritis.
Van Vollenhoven R, Soriano A, McCarthy P, Schwartz R, Garbrecht F, Thorbecke G, et al
J. Immunol. 1988 Aug;141(4):1168-73

Tolerance induction by a poorly arthritogenic collagen II can prevent collagen-induced arthritis.
van Vollenhoven R, Nagler-Anderson C, Soriano A, Siskind G, Thorbecke G
Cell. Immunol. 1988 Aug;115(1):146-55

A cross-reactive idiotype on anti-collagen antibodies in collagen-induced arthritis: identification and relevance to disease.
Nagler-Anderson C, van Vollenhoven R, Gurish M, Bober L, Siskind G, Thorbecke G
Cell. Immunol. 1988 May;113(2):447-61

Physiology of IgD. IX. Effect of IgD on immunoglobulin production in young and old mice.
Swenson C, Van Vollenhoven R, Xue B, Siskind G, Thorbecke G, Coico R
Eur. J. Immunol. 1988 Jan;18(1):13-20

1987

A syngeneic MLR induced in vivo results in T-cell mediated immune suppression.
van Vollenhoven R, Braver J, Francus T, Schwartz R, Thorbecke G, Siskind G
Cell. Immunol. 1987 May;106(2):397-407

InflammationReumatologi